ClinicalTrials.Veeva

Menu

Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

P

Peking University

Status

Unknown

Conditions

Thoracic Neoplasms
Carcinoma
Non-small-cell Lung Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT02833467
PTHO1502

Details and patient eligibility

About

Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations. This study is to evaluate the feasibility and application value by using NGS into identifying genomic mutations in multiple or multifocal primary lung cancers in cell-tumor DNA (ctDNA) from surgical patients

Full description

Tumor samples originating from clinically considered multiple or multifocal primary lung cancer patients were available for mutational analysis. DNA and RNA were extracted from fresh tumor tissue or formalin-fixed, paraffin-embedded (FFPE) tissue. A series of cancer-related genomic alterations including single nucleotide variations (SNVs), short insertions and deletions (InDels), copy number variations (CNVs) and gene rearrangements were identified by a comprehensive NGS Panal . High frequency mutations were also identified in blood sample by droplet digital polymerase chain reaction(ddPCR).

Enrollment

45 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients must have given written informed consent
  • Histopathologically confirmed NSCLC
  • Considered multiple or multifocal primary lung cancer by clinical criteria

Exclusion criteria

  • Malignant tumor history within the past 5 years
  • Patients who received any treatment prior to resection
  • Insufficient tumor tissue or blood sample

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems